Cha Zhanshan, Zang Yan, Guo Huijun, Rechlic James R, Olasnova Lindsay M, Gu Haihui, Tu Xiaohua, Song Haihan, Qian Baohua
Department of Transfusion, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
Tumour Biol. 2013 Dec;34(6):3579-85. doi: 10.1007/s13277-013-0937-2. Epub 2013 Jun 27.
Accumulating evidences indicate that immune dysregulation plays a key role in both lymphomagenesis and patient outcome of chronic lymphocytic leukemia (CLL). Peripheral blood CD4+ CXCR5+ T cells, known as circulating follicular helper T cells (Tfh), can induce B cell activation and production of specific antibody responses. The aim of the study was to investigate changes of circulating Tfh in CLL. Tfh and it subtypes were tested by measuring CD4, CXCR5, CXCR3, and CCR6 in 72 CLL cases and 86 healthy controls using flow cytometry. Data showed that the percentage of Tfh in the peripheral CD4+ T cells was significantly increased in CLL (25.1%) than in controls (8.4%) (p < 0.001). Further analysis revealed that the upregulation of Tfh was contributed by Tfh-th2 subtype and Tfh-th17 subtype. Investigating staging of the cases demonstrated that the prevalence of Tfh was significantly elevated in cases with Binet stage C (37.3%) than those with stage A (20.1 %) or stage B (23.9 %). In addition, we analyzed Tfh in patients with immunoglobulin variable heavy chain (IGHV) gene mutational status. Results presented that Tfh-th17 subtype had clearly higher frequency in patients with IGHV mutation compared to the unmutated cases (p = 0.035). This study suggested the involvement of Tfh in the pathogenesis and progression of CLL, and provided a potential target for treating this disease.
越来越多的证据表明,免疫失调在慢性淋巴细胞白血病(CLL)的淋巴瘤发生和患者预后中都起着关键作用。外周血CD4 + CXCR5 + T细胞,即循环滤泡辅助性T细胞(Tfh),可诱导B细胞活化并产生特异性抗体反应。本研究的目的是调查CLL中循环Tfh的变化。通过流式细胞术检测72例CLL患者和86例健康对照者的CD4、CXCR5、CXCR3和CCR6,以检测Tfh及其亚型。数据显示,CLL患者外周血CD4 + T细胞中Tfh的百分比(25.1%)显著高于对照组(8.4%)(p < 0.001)。进一步分析显示,Tfh的上调是由Tfh-th2亚型和Tfh-th17亚型所致。对病例分期的调查表明,Binet分期为C期的患者中Tfh的患病率(37.3%)显著高于A期(20.1%)或B期(23.9%)的患者。此外,我们分析了免疫球蛋白可变重链(IGHV)基因突变状态患者的Tfh。结果显示,与未突变病例相比,IGHV突变患者中Tfh-th17亚型的频率明显更高(p = 0.035)。本研究提示Tfh参与了CLL的发病机制和进展,并为治疗该疾病提供了一个潜在靶点。